GO
Loading...

Allergan Inc

More

  • NEW YORK, Feb 22- Canada's Valeant Pharmaceuticals International Inc. agreed to acquire gastrointestinal drugmaker Salix Pharmaceuticals Ltd. in an all-cash deal valued at about $10.1 billion, the two companies said on Sunday. The deal is the largest ever for Laval, Quebec- based Valeant, which lost a take-over contest for Allergan Inc last year.

  • Drugmaker Valeant to buy Salix for $14.5 billion Sunday, 22 Feb 2015 | 4:07 PM ET

    Salix, a maker of gastrointestinal drugs that has been courted by at least four potential suitors over the last year, has finally found a buyer.

  • Drugmaker Valeant to buy Salix: Sources Saturday, 21 Feb 2015 | 2:55 PM ET

    The all-cash deal could be announced as soon as Sunday, according to these sources who requested not to be identified.

  • Final Glance: Medical Devices companies Friday, 20 Feb 2015 | 6:00 PM ET

    Allergan rose $2.88 or 1.2 percent, to $234.00. Baxter International Inc. rose$. 48 or. 7 percent, to $67.90. Boston Scientific Corp. rose$. 02 or. 1 percent, to $16.47.

  • Midday Glance: Medical Devices companies Friday, 20 Feb 2015 | 1:36 PM ET

    Allergan rose $3.00 or 1.3 percent, to $234.12. Baxter International Inc. fell$. 75 or 1.1 percent, to $66.68. Boston Scientific Corp. fell$. 07 or. 4 percent, to $16.38.

  • NEW YORK, Feb 20- Valeant Pharmaceuticals International Inc is close to a deal to acquire bowel drug maker Salix Pharmaceuticals Ltd for around $160 per share, according to a person directly familiar with the matter. A deal of that size would be the largest ever for Valeant, which lost a takeover contest for Allergan Inc last year. The usually acquisitive Valeant...

  • Early Glance: Medical Devices companies Friday, 20 Feb 2015 | 10:50 AM ET

    Allergan rose$. 34 or. 1 percent, to $231.46. Baxter International Inc. fell $1.29 or 1.9 percent, to $66.13. Boston Scientific Corp. fell$. 13 or. 8 percent, to $16.32.

  • Final Glance: Medical Devices companies Thursday, 19 Feb 2015 | 6:03 PM ET

    Allergan rose $1.62 or. 7 percent, to $231.12. Baxter International Inc. fell$. 98 or 1.4 percent, to $67.42. Boston Scientific Corp. fell$. 23 or 1.4 percent, to $16.45.

  • Midday Glance: Medical Devices companies Thursday, 19 Feb 2015 | 1:28 PM ET

    Allergan rose $1.10 or. 5 percent, to $230.60. Baxter International Inc. fell$. 91 or 1.3 percent, to $67.49. Boston Scientific Corp. fell$. 30 or 1.8 percent, to $16.38.

  • Early Glance: Medical Devices companies Thursday, 19 Feb 2015 | 10:51 AM ET

    Allergan rose $1.13 or. 5 percent, to $230.63. Baxter International Inc. fell$. 87 or 1.3 percent, to $67.53. Johnson& Johnson fell$. 08 or. 1 percent, to $99.89.

  • Forget Buffett. Follow these top investors Wednesday, 18 Feb 2015 | 12:46 PM ET
    Jeffrey Smith, Starboard Value

    CNBC.com found the best performing investors you probably have never heard of, but are beating the market these days. Here are their top picks.

  • NEW YORK, Feb 18- Actavis Plc, a generic drugmaker that has been steadily acquiring branded medicines, said it will change its name to Allergan Inc after it completes its planned $66 billion purchase of the Botox maker, signaling its growing focus on patent-protected drugs. Actavis, which began as a New Jersey- based generics company called Watson, took its current...

  • UPDATE 2-Actavis beats profit estimates, raises forecast Wednesday, 18 Feb 2015 | 9:11 AM ET

    Feb 18- Actavis Plc posted a better-than-expected adjusted quarterly profit and raised its full-year earnings forecast, saying it expected strong sales of its new branded drugs. Actavis agreed to buy Allergan Inc last November for $66 billion, outbidding a hostile offer by activist investor William Ackman and Valeant Pharmaceuticals International Inc.

  • Actavis to take Allergan name  Wednesday, 18 Feb 2015 | 7:42 AM ET

    Actavis President & CEO Brent Saunders explains the new corporate name, and the strong earnings beat. "We keep surprising people," says Saunders.

  • Actavis, which bought Botox-maker Allergan Inc in November, makes drugs from research in its own pipeline, and copy cat versions of other popular drugs. Sales of the Actavis's branded drugs nearly tripled to $1.83 billion in North America in the fourth quarter, accounting for 45 percent of total revenue. For the fourth quarter ended Dec. 31, Actavis's net loss...

  • Two billionaires, opposite approaches to investing Friday, 13 Feb 2015 | 2:25 PM ET
    Ray Dalio, left, and Bill Ackman

    It was man versus machine when Bill Ackman interviewed Ray Dalio in New York.

  • Allergan CEO: Bill Ackman battle was all-consuming Tuesday, 10 Feb 2015 | 9:36 AM ET

    Allergan chief David Pyott tells CNBC that dealing with "raiders" like Bill Ackman and Valeant Pharmaceuticals was a full-time job.

  • Allergan CEO: Fighting Ackman 'all consuming'  Tuesday, 10 Feb 2015 | 8:03 AM ET

    David Pyott, Allergan chairman & CEO, discusses the company's historic quarter, Bill Ackman's failed attempt to take over the company and the decision to subdivide the management team.

  • WASHINGTON, Feb 10- For the first time in 20 years, patients suffering from the eye disease glaucoma may soon have new treatments as several young companies look to shake up the $5.6 billion global market. No new class of medicine has been introduced since Pfizer Inc's N> Xalatan, known generically as latanoprost, in 1996.. The newcomers aim to disrupt...

  • M&A experts forecast there will be more major pharma deals in 2015 — but the U.K. won’t be a focus and the deals won’t be done for tax reasons.